• A novel chimeric protein with enhanced cytotoxic effects on breast cancer in vitro and in vivo

    10 days ago - By Wiley

    Abstract
    In our previous study, we reported the design and recombinant production of the p28-apoptin as a novel chimeric protein for breast cancer treatment. This study aimed to evaluate the inhibitory activity of the chimeric protein against BC cells in vitro and in vivo. We developed a novel multifunctional protein, consisting of p28, as a tumor-homing killer peptide fused to apoptin as a tumor-selective killer. The chimeric protein showed significantly higher toxicity in BC cell lines dose-dependently than in non-cancerous control cell lines. IC 50 values were 1.41 μM, 1.38 μM, 6.13 μM...
    Read more ...